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BACKGROUND: Prenatal inﬂammatory mechanisms may play a role in the pathogenesis of psychiatric disorders
and could be relevant for attention-deﬁcit/hyperactivity disorder (ADHD). We investigated maternal chronic somatic
diseases with immune components as possible risk factors for ADHD in offspring.
METHODS: We performed a population-based nested case-control study by linking data from longitudinal
Norwegian registers. We included all individuals born during the period 1967–2008 and alive at record linkage
(2012). Individuals receiving ADHD medication during the years 2004–2012 were deﬁned as patients with ADHD (N 5
47,944), and all remaining individuals (N 5 2,274,713) were deﬁned as control subjects. The associations between
maternal diseases and ADHD in offspring were analyzed using logistic regression models.
RESULTS: The following chronic diseases with immune components were related to ADHD in offspring: multiple
sclerosis (adjusted odds ratio [OR] 5 1.8; 95% conﬁdence interval [CI] 5 1.2–2.5), rheumatoid arthritis (adjusted OR
5 1.7; 95% CI 5 1.5–1.9), type 1 diabetes (adjusted OR 5 1.6; 95% CI 5 1.3–2.0), asthma (adjusted OR 5 1.5; 95%
CI 5 1.4–1.6), and hypothyroidism (adjusted OR 5 1.2; 95% CI 5 1.1–1.4). In contrast, chronic hypertension and
type 2 diabetes showed no signiﬁcant associations. Estimates were almost unchanged with additional adjustment for
parental ADHD, infant birth weight, and gestational age. Although point estimates for male and female offspring were
different for some diseases (e.g., maternal asthma [adjusted OR 5 1.7; 95% CI 5 1.5–1.8 for female offspring and
adjusted OR 5 1.5; 95% CI 5 1.4–1.6 for male offspring]), none of the associations differed signiﬁcantly by
offspring sex.
CONCLUSIONS: Several maternal somatic diseases with immune components were found to increase the risk of
ADHD in offspring. The associations could involve several causal pathways, including common genetic predis-
position and environmental factors, and increased insight into the mechanisms behind these relationships could
enhance our understanding of the etiology of ADHD.
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Risk factorsISShttp://dx.doi.org/10.1016/j.biopsych.2015.11.024Attention-deﬁcit/hyperactivity disorder (ADHD) is a neurode-
velopmental disorder that affects children and adults world-
wide, with prevalence estimates 5% in children (1) and 3%
in adults (2). The prevalence varies among studies; in a
Norwegian study of children 8–10 years old, it was estimated
to be 1.7% (3). The disorder is two to three times more
frequent in boys than girls (4), although the sex distribution
becomes more equal with age (5). The etiology of ADHD is
complex, involving interactions between genetic and environ-
mental factors, and many risk pathways may lead to its clinical
features (6).
Previous studies described several prenatal and perinatal
risk factors for ADHD. Low birth weight (7–12), preterm birth
(8,9,13–16), and small size for gestational age (8,16) have
consistently been related to an increased risk of ADHD or& 2016 Society of Biological Psychiatry.
N: 0006-3223
SEE COMMENTAADHD symptoms. Exposure to maternal smoking (17) and
other substances in utero (6) also have been reported to be
associated with increased risk of ADHD. Furthermore, associ-
ations with ADHD in offspring have been found for some
maternal medical conditions, including obesity (18) and epi-
lepsy (8). It has been hypothesized that ADHD may be caused
by an exaggerated central nervous system inﬂammatory
response in the fetus caused by maternal inﬂammation, such
as in allergy or autoimmune disease (19). It is difﬁcult to draw
conclusions about causal pathways, as associations between
maternal diseases and ADHD in offspring can involve several
different, partly overlapping, causal pathways. Common
genetic predisposition, environmental factors such as mater-
nal medication exposures, and fetal inﬂammatory response
are examples of such causes. Because few studies haveThis is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). 1
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Psychiatryevaluated maternal immune system diseases, we investigated
whether such diseases were associated with ADHD in off-
spring using data from nationwide registers in Norway. Addi-
tionally, we assessed whether these risk factors differed by
patient’s sex.
METHODS AND MATERIALS
This study was approved by the Norwegian Data Protection
Authority, the Norwegian Directorate of Health, and the
Regional Committee for Medical and Health Research Ethics
(2011/2272). The data were treated anonymously, and so no
further consent was required.
We performed a population-based nested case-control
study by linking information from the Medical Birth Registry
of Norway (MBRN), the Norwegian Prescription Database
(NorPD), and the National Educational Database. In a sensi-
tivity analysis, we also included data from the Norwegian
Patient Registry.
The nationwide MBRN was established in 1967 and con-
tains information on nearly 2.6 million births up to 2012. The
registration is based on compulsory notiﬁcation and includes
information on all live births and fetal losses/stillbirths from 16
weeks of gestation. A standardized form is used to document
information on maternal health before and during pregnancy,
complications during pregnancy and delivery, and birth out-
comes. For the years 1967–1998, information was mainly
documented as free text speciﬁcations to items such as
“Maternal health before pregnancy,” “Maternal health during
pregnancy,” “Complications in relation to birth,” and “Infant
outcomes.” A more detailed documentation form, introduced
in 1999, included information on maternal smoking habits and
check boxes for speciﬁc conditions in addition to free text (20).
The NorPD covers all prescribed drugs dispensed to individ-
uals in Norway since 2004. From 2008, NorPD includes
diagnostic codes (ICD-10/International Classiﬁcation of Pri-
mary Care, Second edition) for reimbursed drugs (21). The
level of education of all Norwegian inhabitants from 16 years
of age is registered annually in the National Education Data-
base. The Norwegian Patient Registry provides information on
diagnoses of all patients having contact with specialist health
services from 2008.
Study Population and Variable Information
Record linkage was established by using the personal identity
number unique to every Norwegian resident. This study
included all individuals born from 22 weeks of gestation or
with birth weight at least 500 g in Norway during the period
1967–2008 who were still alive at record linkage in 2012 (N 5
2,322,657).
Cases in this study consisted of all registered individuals in
MBRN born during the period 1967–2008 who had been
prescribed and dispensed ADHD medications during the years
2004–2012 and were .3 years old at last prescription.
The dispensed and reimbursed ADHD medications meth-
ylphenidate (Anatomical Therapeutic Chemical Classiﬁcation
System [ATC] code N06BA04), atomoxetine (ATC code
N06BA09), and racemic amphetamine (ATC code N06BA01)
were extracted from the NorPD. The use of ADHD medication
is restricted in Norway; medical treatment of ADHD is2 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalinitiated only after thorough assessment of the patient by a
specialist in psychiatry or child psychiatry. Dexamphetamine
(ATC code N06BA02) was off label in Norway during
the study period and is not used as a ﬁrst-option treatment
and therefore was not included in our case deﬁnition.
Drugs used to treat ADHD may also be used for narcolepsy.
Using the reimbursement codes from 2008, we found that
117 individuals (1.4%) were dispensed stimulant medication
with the indication narcolepsy, and these were excluded from
the case group. Thus, for patients who were dispensed
medicine in the period 2004–2008 only, there may be a
small number of individuals with narcolepsy left in the
case group.
The control group included all registered individuals in
MBRN born during the period 1967–2008 and alive at record
linkage who had not been dispensed ADHD medication during
the period 2004–2012. The 117 individuals who were dis-
pensed stimulant drugs for narcolepsy in the period 2008–
2012 were included in the control population (N 5 2,274,713).
Thus, by design, the control group included people with a
diagnosis of ADHD who did not receive ADHD medication or
who had used (and stopped using) ADHD medication before
2004 when the NorPD was established.
Maternal educational level was used as a measure for
socioeconomic level and grouped in three categories: low
(,10 years), medium (10–12 years), and high (.12 years).
Description of Variables
As potential prenatal risk factors for ADHD, we studied the
following maternal chronic somatic diseases, all with inﬂam-
matory or immune components of pathologic relevance: multi-
ple sclerosis, asthma, rheumatoid arthritis, hypothyroidism,
hyperthyroidism, and pregestational type 1 diabetes. Preges-
tational type 2 diabetes and chronic hypertension were also
included. Because we assumed that immunologic/inﬂamma-
tory mechanisms are less strongly involved in these condi-
tions, they were included to serve as contrasting chronic
diseases in the analyses. We chose the diseases included in
the analyses using several criteria. Our focus was immune
system diseases, and we selected diseases for which the
MBRN registration was previously validated (pregestational
type 1 and 2 diabetes, rheumatic arthritis, asthma) (20,22),
diseases that were previously described in the literature with
data from MBRN (multiple sclerosis) (23–25), diseases for
which the MBRN notiﬁcation form from 1999 had speciﬁc
check boxes (asthma, diabetes type 1 and 2, rheumatic
arthritis and chronic hypertension), and diseases for which
the MBRN reported signiﬁcantly increasing time trends in
prevalence and for which associations with ADHD in offspring
was previously discussed (thyroid disorders) (26–29). The
maternal diseases were diagnosed before or during pregnancy
for the target individual. Pregestational diabetes, without
subtyping, has been registered in the MBRN from 1967 and
speciﬁed as type 1 and type 2 since 1988 (n = 32,984 cases,
n = 1,113,011 controls).
Statistical Analyses
Analyses were performed with PASW Statistics 18 (SPSS
Hong Kong, Quarry Bay, Hong Kong) and Stata version 13
Table 1. Sociodemographic Characteristics of Patients
With ADHD and Control Subjects in Norway, 1967–2012
ADHD Patients
(N 5 47,944),
n (%)
Control Subjects
(N 5 2,274,713),
n (%)
Male Sex 31,514 (65.7) 1,158,422 (50.9)
Year of Birth
1967–1978 6517 (13.6) 675,929 (29.7)
1979–1988 8443 (17.6) 485,773 (21.4)
1989–1998 23,501 (49.0) 556,250 (24.5)
1999–2008 9483 (19.8) 556,761 (24.5)
Marital Status of Mother (n 5 47,314) (n 5 2,246,177)
Single 7588 (16.0) 187,218 (8.3)
Married/cohabiting/partnership 38,535 (81.5) 2,028,282 (90.3)
Divorced/separated/widowed 850 (1.8) 19,479 (.9)
Other/unknown 341 (.7) 11,198 (.5)
Parity (n 5 47,314) (n 5 2,246,177)
Para 0 21,015 (44.4) 925,190 (41.2)
Para 1 15,886 (33.6) 784,852 (34.9)
Para 21 10,413 (22.0) 536,135 (23.9)
Maternal Age (Years) (n 5 47,314) (n 5 2,246,176)
,20 4367 (9.2) 127,279 (5.7)
20–34 39,150 (82.8) 1,882,572 (83.8)
$35 3797 (8.0) 236,325 (10.5)
Paternal Age (Years) (n 5 46,689) (n 5 2,230,886)
,20 1149 (2.5) 28,334 (1.3)
20–39 42,398 (90.8) 2,025,111 (90.8)
$40 3142 (6.7) 177,441 (8.0)
Educational Level (Mother)a (n 5 46,995) (n 5 2,228,246)
Low 15,528 (33.0) 529,358 (23.8)
Medium 20,028 (42.6) 970,395 (43.6)
High 11,439 (24.3) 728,493 (32.7)
ADHD, attention-deﬁcit/hyperactivity disorder.
aMaternal educational level: high (.12 years of education), medium
(10–12 years of education) and low (#9 years of education).
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Psychiatry(StataCorp LP, College Station, Texas). Data were analyzed
using descriptive statistics with χ2 tests, and we calculated
relative risks and crude odds ratios (ORs) for categorical
variables. We used logistic regression analyses to calculate
ORs adjusting for the following factors: maternal age at
delivery, parity, time period of birth (5-year categories),
maternal marital status, and maternal educational level. All
factors were modeled as categorical variables as speciﬁed in
the footnotes in Tables 1 and 2 and Table S1 in Supplement 1.
We further included one model adding maternal and paternal
use of ADHD medication from NorPD (2004–2012) as adjust-
ment variables. This information was used as a proxy for
maternal and paternal ADHD. In a ﬁnal model, we included all
the studied maternal diseases in addition to infant birth weight
and gestational age. We also included maternal smoking in a
subanalysis for individuals born after 1998, when smoking
information was available. We stratiﬁed analyses by sex and
compared associations between male and female offspring.
Crude and adjusted ORs were reported with 95% conﬁdence
intervals (CIs). We also analyzed mothers with more than onebirth by calculating OR with robust standard errors using the
mother as the cluster variable.RESULTS
Sociodemographic Characteristics
Overall, there was a larger male proportion in the ADHD group
(65.7%) (Table 1) compared with the control group (50.9%).
Mothers of offspring with ADHD were younger, were more
often single, and had lower educational level compared with
mothers of control subjects. Similarly, fathers of offspring with
ADHD were younger and had lower education compared with
fathers of control subjects (data not shown).
Association Between Maternal Somatic Diseases
and ADHD in Offspring
We found higher frequencies of several immune system
diseases among mothers of offspring with ADHD compared
with mothers of control subjects (Table 2), with signiﬁcantly
higher overall odds for maternal multiple sclerosis, rheumatoid
arthritis, type 1 diabetes, asthma, and hypothyroidism. Mater-
nal chronic hypertension, type 2 diabetes, and hyperthyroid-
ism were not associated with ADHD in offspring.
The associations between maternal immune-related dis-
ease and ADHD in offspring did not depend on offspring sex.
Figure 1 shows that although the point estimates for the
maternal disease–offspring ADHD associations to some extent
differ between male and female offspring, CIs overlap. How-
ever, for maternal asthma, where the point estimate for ADHD
in female offspring was 1.7 and for male offspring was 1.5, the
CIs around the estimates overlapped only slightly (95% CI 5
1.5–1.8 for female offspring and 95% CI 5 1.4–1.6 for male
offspring). Furthermore, for maternal multiple sclerosis and
ADHD in offspring, where the point estimates were 2.2 for
female offspring and 1.6 for male offspring, the CIs were
broad, and we may have lacked power to detect a possible
true sex difference.
We repeated all analyses with data from 1999 to adjust for
maternal smoking habits. The results were not altered notice-
ably. For example, adjusted OR between maternal asthma and
ADHD in offspring was 1.5 (95% CI 5 1.4–1.6), and when also
adjusting for smoking, OR was 1.7 (95% CI 5 1.5–2.0) for
female offspring and 1.4 (95% CI 5 1.3–1.6) for male offspring.
Although we set the level of signiﬁcance at p , .05, all
the above-listed signiﬁcant results had p values , .01.
The associations with maternal asthma, rheumatoid arthritis,
and type 1 diabetes had p values , .0001 (Table S1 in
Supplement 1).
Sensitivity Analyses
Because we deﬁned our ADHD cases only on the basis of
dispensed ADHD medication, it may be that our cases
represent a special subgroup of patients. For the period
2008–2012, we also had available data from the Norwegian
Patient Registry. Of the 12,223 individuals registered with an
ADHD diagnosis in the Norwegian Patient Registry, only 2040
(17%) individuals did not receive ADHD drugs. Adding theseBiological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal 3
Table 2. Maternal Chronic Diseases and ADHD in Offspring: Results From Unadjusted and Different Logistic
Regression Models
ADHD Group
(N 5 47,944),
n (%)
Control Group
(N 5 2,274,713),
n (%)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)a
Adjusted OR Model
Including Maternal and
Paternal ADHDb
Expanded Model
Adjusted OR
(95% CI)c
Asthma 1857 (3.9) 47519 (2.1) 1.9 (1.8–2.0) 1.5 (1.4–1.6) 1.5 (1.4–1.5) 1.5 (1.5–1.6)
Rheumatoid
Arthritis
250 (.5) 5813 (.3) 2.0 (1.8–2.3) 1.7 (1.5–1.9) 1.7 (1.5–1.9) 1.6 (1.4–1.9)
Hypothyroidism 235 (.5) 11,625 (.5) 1.0 (.8–1.1) 1.2 (1.1–1.4) 1.2 (1.0–1.3) 1.2 (1.0–1.4)
Hyperthyroidism 68 (.1) 3070 (.1) 1.1 (.8–1.3) 1.2 (.9–1.5) 1.1 (.9–1.4) 1.2 (.9–1.5)
Type 1
Diabetesd
88 (.3) 2825 (.3) 1.1 (.9–1.3) 1.6 (1.3–2.0) 1.7 (1.3–2.1) 1.5 (1.2–1.9)e
Type 2
Diabetesd
19 (.1) 1135 (.1) .6 (.4–.9) 1.1 (.7–1.8) 1.2 (.7–1.9) 1.1 (.7–1.8)e
Multiple
Sclerosis
31 (.1) 880 (0) 1.7 (1.2–2.4) 1.8 (1.2.–2.5) 1.8 (1.3–2.6) 1.8 (1.2–2.6)
Hypertension,
Chronic
155 (.3) 6496 (.3) 1.1 (1.0–1.3) 1.1 (.9–1.3) 1.1 (.9–1.3) 1.1 (.9–1.2)
ADHD, attention-deﬁcit/hyperactivity disorder; CI, conﬁdence interval; OR, odds ratio.
aAdjusted by year of birth (5-year interval 1967–2008), parity (para 0, para 1, para 21), mother’s age at birth (,20, 20–24, 25–29, 30–34, 35–39,
.39 years), mother’s educational level (low/medium/high), mother’s marital status (married/cohabiting/partnership, single, divorced/separated/
widowed, other/unknown).
bAdjusted by the same covariates listed in a adding maternal and paternal use of ADHD medication.
cModel including all risk diseases as covariates listed in a in addition to birth weight (5 categories [,1500, 1500–1999, 2000–2499, 2500–4499,
$4500 kg]) and gestational age (5 categories [22–31 weeks, 32–36 weeks, 37–41 weeks, $42 weeks]).
dData from 1989 and later.
eAll variables, including risk diseases, selected from 1989 and later when analyzing diabetes.
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results (data not shown).
We also ran several additional models. In one model, we
included maternal and paternal use of ADHD medication as
possible confounding variables. Overall, the associations were
unchanged or only slightly weakened (Table 2). We also looked
at overall offspring ADHD including all risk diseases as
covariates, with additional adjustment for gestational age
and infant birth weight. None of the estimates changed much
(Table 2). Results also did not change much when calculating
ORs with robust standard errors and the mother as cluster
variable (data not shown).Figure 1. Associations (adjusted odds ratios with 95% conﬁdence
intervals) between maternal diseases and attention-deﬁcit/hyperactivity
disorder (ADHD) in offspring by sex in Norway, 1967–2012. Female patients
with ADHD (white circles); male patients with ADHD (black circles).
4 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalAs shown in Table 2, the OR for type 1 diabetes increased
from 1.1 (95% CI 5 .9–1.3) in the unadjusted model to 1.6
(95% CI 5 1.3–2.0) in the adjusted model. To explore this
association further, we performed an additional analysis using
data after 1998, when a precoded checkbox for type 1
diabetes was introduced in the MBRN registration form. In
this analysis, the unadjusted OR (1.5; 95% CI 5 1.2–2.0) was
similar to the adjusted OR (1.6; 95% CI 5 1.2–2.0). Thus, we
consider that the low OR for type 1 diabetes association in the
early time period may be an artifact caused by insufﬁcient data
collection.DISCUSSION
This large nationwide register-based study with prospective
data showed that several chronic maternal diseases with
immune components, including multiple sclerosis, rheumatoid
arthritis, asthma, hypothyroidism, and type 1 diabetes were
associated with ADHD in offspring. Maternal multiple sclerosis
and rheumatoid arthritis were associated with 80% and 70%
higher odds of ADHD in offspring, respectively, and maternal
asthma was associated with 50% higher odds, independent of
maternal smoking. There were no statistically signiﬁcant sex
differences, although we may have lacked power to detect
possible true sex differences for some maternal diseases.
This study has several strengths. It is large and includes
the entire Norwegian population over a period of 45 years.
The genetic homogeneity of the Norwegian population is an
advantage when studying other biological risk factors as
well as external risk factors. The unique Norwegian per-
sonal identity number ensured a valid linkage between the
registers involved. The data were prospectively collected with
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Psychiatrycompulsory notiﬁcation, minimizing selection and follow-up
bias. On one hand, by using the nationwide prescription
database to deﬁne the case population, thus including only
patients who were medicated with reimbursement as cases,
we ensured that cases had a valid diagnosis of ADHD. On the
other hand, the ADHD cases in this study probably represent
the most severely affected patients, as medical treatment is
indicated only when substantial loss of function is present. The
diagnostic classiﬁcation system used in Norway is ICD-10. We
use data from NorPD during 2004-2012 to deﬁne our cases.
According to national guidelines published during these years,
ADHD should be diagnosed according to ICD-10 criteria,
although allowing the inattentive subtype in DSM-IV as
sufﬁcient for the diagnosis. Other psychiatric disorders may
also be present, as long as the ADHD criteria are fulﬁlled
before the comorbid disorder appears. As some clinicians may
have used the more restricted ICD-10 criteria, persons with the
inattentive subtype may be underrepresented in our case
group. Thus, our results may be most valid for more severe
cases of ADHD and the combined subgroup. Moreover, in the
Norwegian population, the indications for starting ADHD
medication for treating ADHD symptoms could vary slightly
from other populations, which may limit to a certain degree the
generalizability of our results. Still, our sensitivity analysis
showed that only 17% of registered patients during the period
2008–2012 did not receive ADHD medication. Some people
included in the control group could have used medication for
ADHD before 2004 when NorPD was established; however,
this would tend to weaken the associations. Because our
control group is very large, the few false-negative ADHD cases
should not represent an important source of bias.
We report a robust association between ADHD in offspring
and maternal disorders with underlying immune factors,
including multiple sclerosis, rheumatoid arthritis, asthma,
hypothyroidism, and type 1 diabetes. It has been suggested
that maternal diseases with immune components, such as
infections, allergy, and autoimmune disease, may cause an
exaggerated central nervous system inﬂammatory response in
the fetus (19). Subsequently, this exaggerated inﬂammatory
response could harm the developing brain. Inﬂammatory
mechanisms are believed to play a role in the pathogenesis
of psychiatric disorders such as schizophrenia (30) and autism
(31), and similar mechanisms may be relevant for the develop-
ment of ADHD. Altered fetal neurodevelopment has been
associated with diverse maternal infections during pregnancy,
suggesting the maternal immune response in itself can alter
fetal brain development, as shown in a primate model (32).
Ghassabian et al. (27) reported that children of mothers with
elevated levels of maternal thyroid peroxidase antibodies had
more ADHD symptoms. These antibodies could play a part
both in the development of autoimmune thyroid disease
leading to maternal hypothyroidism and in the fetal neuronal
development leading to ADHD.
Patients with ADHD have an increased risk of asthma, the
association being highest in female patients (33). However, the
present study is the ﬁrst to show an association between
maternal asthma and ADHD in offspring. It was unchanged
when adjusting for parental ADHD medication as well as with
additional adjustment for maternal smoking and could support
shared etiological pathways to ADHD and asthma.We did not ﬁnd associations between maternal chronic
hypertension or type 2 diabetes and ADHD in offspring.
Although it has been proposed that inﬂammation also may
contribute to these disorders (34,35), these chronic conditions
are less clearly related to immune system components
compared with rheumatoid arthritis and multiple sclerosis, in
which the immunopathology is well deﬁned; this indicates that
maternal immunological factors could play a role in the
pathogenesis of ADHD in offspring.
We controlled for many potential and known confounders.
Information on maternal smoking was available only from
1999. However, results using data from 1999 with additional
adjustment for smoking were in agreement with the main
results. Including maternal and paternal use of ADHD medi-
cation in the regression model weakened some of the
associations slightly, but they were still in line with the main
results.
This study has several limitations. The diagnostic validity of
reported diagnosis in the MBRN has not been formally studied
for all the studied diseases. The sensitivity of reported
rheumatoid arthritis (22) and type 1 diabetes (20) in MBRN is
high, estimated to be 88% for rheumatoid arthritis and 90% for
type 1 diabetes. For severe asthma, the sensitivity is lower
(73%) (20). However, potentially missed maternal cases would
most likely attenuate the associations.
The observational design of the study does not allow for
deﬁnite causal inference. The observed associations could
be explained by unmeasured environmental confounding,
such as maternal medication use during pregnancy,
unmeasured genetic confounding, or an inﬂammatory
response in the fetus; furthermore, these pathways could
overlap.
It is known that ADHD is a partially genetic disorder; the
heritability has been estimated to .7–.9 (36,37). Environmental
factors and the interplay between genetic and environmental
factors are also important (38). Analyses of genome-wide
genetic markers demonstrated genetic correlations between
many traits as well as between somatic and psychiatric
disorders (39). Shared genetic susceptibilities could explain
some of our ﬁndings. For example, the SLC9A9 gene has been
implicated in ADHD and multiple sclerosis (40–42). We did not
have data on chronic immune diseases in the fathers in the
present data ﬁle. However, in a different data set, we had
information on prescribed medications of fathers. We used this
data set to look at fathers who had been prescribed insulin
(2% of the fathers), thyroid replacement drugs (2%), and
antiasthmatic drugs (13%) as indications of paternal type 1
diabetes, hypothyroidism, and asthma. Adjusting for the same
variables as in the maternal models, we found an adjusted OR
for ADHD in offspring related to paternal type 1 diabetes of 1.2
(95% CI = 1.1–1.3), paternal hypothyroidism of 1.1 (95% CI =
1.0–1.2), and paternal asthma of 1.3 (95% CI = 1.3–1.3). In
other words, even though there were statistically signiﬁcant
relationships for paternal asthma and type 1 diabetes with
ADHD in offspring, the risk estimates were lower than the risk
estimates found for maternal chronic immune disease. This
ﬁnding is an indication that at least some of the relationship
between maternal chronic immune disease and ADHD in
offspring may be explained by inﬂammatory mechanisms
during pregnancy.Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal 5
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PsychiatryWe adjusted for maternal and paternal ADHD, but we had
information about parental ADHD only through data registered
in the NorPD for parents who had been dispensed ADHD
medication during the period 2004–2012. However, before the
late 1990s, ADHD was mainly thought of as a childhood
disorder, and adults were not given the diagnosis. Therefore,
information about parental ADHD is lacking in all data sources
until the late 1990s. We cannot exclude residual confounding
by shared genetic factors in the present study.
The mechanisms behind our reported ﬁndings can also be
related to effects of maternal medication use during preg-
nancy. Acetaminophen used in pregnancy has been associ-
ated with an increased risk of hyperkinetic disorder in offspring
(43), although the mechanism behind this association is not
understood. Acetaminophen may act as a hormone disruptor,
interfering with thyroid and reproductive function important for
brain development (44). However, it is not completely under-
stood if the association is due to a toxic effect of acetamino-
phen itself or the underlying causes for women taking these
medications during pregnancy. Use of antipsychotics and
selective serotonin reuptake inhibitors in pregnancy may affect
fetal and infant neurobehavioral development (45,46). It is
possible that women with chronic immunological disorders
use medications such as acetaminophen and selective sero-
tonin reuptake inhibitors during pregnancy more frequently
than women without such disorders. Certain antiasthmatic
drugs are associated with an increased risk of birth defects in
offspring (47) and could theoretically affect neurodevelopment.
However, severe maternal asthma exacerbations are also
associated with an increased risk of birth defects in offspring
(48). With our data, we could not separate the possible effects
of medication taken in pregnancy for the studied diseases
from the possible direct effects of the underlying diseases.
Inﬂammatory response in the fetus can also explain our
ﬁndings. Abnormal exposure of the fetus to immunomodula-
tory molecules may play a crucial role in linking adverse
pregnancy experiences with altered fetal development. Cyto-
kines are involved in the modulation of the immune system,
and elevated cytokine levels resulting from chronic inﬂamma-
tion may affect fetal development in different ways: either
directly interfering with neuronal development or by epigenetic
mechanisms resulting in altered gene expression (49). This
example shows that the activation of the immune system may
be a causative agent in the development of neurodevelop-
mental disorders.
People with chronic illnesses are more frequently in contact
with health care services compared with healthy people.
Symptoms of ADHD exhibited by their children could be more
easily detected and diagnosed than such symptoms in
children of mothers without chronic disorders. However, in
this case, we would have expected a more uniform increased
risk associated with all chronic disorders, including chronic
hypertension and type 2 diabetes. In Norway, women of
childbearing age with chronic hypertension and type 2 dia-
betes are closely followed by the family doctor; this would be
the natural place to focus on family issues, such as ADHD
symptoms in the children.
Besides immunological processes, other disease-related
factors may be involved in the association between chronic
maternal disease and ADHD in offspring, as ADHD is considered6 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journala multifactorial disorder. Although epilepsy is not viewed as an
disease with immune components, a clear association was
previously reported between maternal epilepsy and ADHD in
offspring (8). This association may have several explanations,
such as teratogenic effects of antiepileptic medication (49) or
fetal hypoxic states caused by maternal seizures. Genetic
factors may also be important (50). Thus, different maternal
disorders with different pathophysiology may lead to ADHD in
the offspring through different underlying pathways.
In conclusion, maternal chronic diseases with immune
components as part of the pathogenetic mechanism (multiple
sclerosis, type 1 diabetes, hypothyroidism, rheumatoid arthri-
tis, and asthma) were associated with increased risk of ADHD
in offspring. The associations did not differ by sex. The
etiology of ADHD is probably multifactorial, and the mentioned
associations can reﬂect different causal pathways to ADHD.
Maternal disease may impact fetal development through
common genetic factors, through environmental factors, or
directly through an altered fetal immune response, leading to
ADHD in offspring. Further studies are needed to elucidate the
mechanisms underlying these relationships, clarifying how
genetic vulnerabilities may interact with environmental factors
to shape disease risk and clinical presentation. Increased
understanding of these pathways could pave the way for
new preventive and treatment strategies targeting neurodeve-
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